BeiGene filed its 2024 Interim Report for the six months ended June 30, 2024, with the STAR Market of the Shanghai Stock Exchange on August 29, 2024. The report, prepared under PRC GAAP, includes additional financial information as required by PRC Securities Laws.The company disclosed R&D expenses for key products and projects under U.S. GAAP. Total R&D expenses reached $915.1M, up from $831.3M in the same period last year. Zanubrutinib and tislelizumab remained top priorities with $62.9M and $34.5M in R&D spending, respectively. Notably, Bcl-2 (BGB-11417) saw a significant increase to $38.6M from $17.5M YoY.BeiGene highlighted key differences between PRC GAAP and U.S. GAAP in areas such as share-based compensation, income taxes, and lease accounting. The report is available in Chinese on the Shanghai Stock Exchange website but is not considered filed with the SEC.

BeiGene filed its 2024 Interim Report for the six months ended June 30, 2024, with the STAR Market of the Shanghai Stock Exchange on August 29, 2024. The report, prepared under PRC GAAP, includes additional financial information as required by PRC Securities Laws.The company disclosed R&D expenses for key products and projects under U.S. GAAP. Total R&D expenses reached $915.1M, up from $831.3M in the same period last year. Zanubrutinib and tislelizumab remained top priorities with $62.9M and $34.5M in R&D spending, respectively. Notably, Bcl-2 (BGB-11417) saw a significant increase to $38.6M from $17.5M YoY.BeiGene highlighted key differences between PRC GAAP and U.S. GAAP in areas such as share-based compensation, income taxes, and lease accounting. The report is available in Chinese on the Shanghai Stock Exchange website but is not considered filed with the SEC.